Results of Competition: Digitalisation of Medicines Manufacturing: Challenge Fund

Competition Code: 1810_CRD_ASHN_DIGMM

Total available funding is £8 million

Note: These proposals have succeeded in the assessment stage of this competition. All are subject to grant offer and conditions being met.

Participant organisation names	Project title	Proposed project costs	Proposed project grant
Autolus Limited	Digital Delivery of Advanced Therapies	£2,618,338	£1,309,169

Note: you can see all Innovate UK-funded projects here: https://www.gov.uk/government/publications/innovate-uk-funded-projects
Use the Competition Code given above to search for this competition's results

Project description - provided by applicants
Advanced Therapies have come of age. The spectacular clinical results demonstrated by novel gene-engineered T-cell therapies, with subsequent regulatory approvals in the US and EU, have confirmed the commercial reality of a new class of therapeutics that offer real hope to patients who are bereft of effective treatment options. But behind this hope lies a deep concern that problematical scalability will severely limit patient access to these therapies. Current Supply Chain technologies and Delivery approaches are inadequate to address the needs of complex madicines that require individual manufacture and a 'closed loop' supply chain whereby the hospital and patient themselves are both the provider of input material and the receiver of a personalised medicine. What is required is a sophisticated approach that allows for flawless tracking and tracing of each batch both during manufacture and during delivery. Integratred into this supply chain is a series of intelligent systems that manage all aspects of manufacture, thus permitting the efficient and scalable certification and release of thousands of batches without any compromise to Product Quality. This Project will pilot these technologies at scale and integrate those findings into a full scale UK-based Advanced Therapies Manufacuring Centre. Keywords: Advanced Therapies; Personalised Medicines

Results of Competition: Digitalisation of Medicines Manufacturing: Challenge Fund

Competition Code: 1810_CRD_ASHN_DIGMM

Total available funding is £8 million

Note: These proposals have succeeded in the assessment stage of this competition. All are subject to grant offer and conditions being met.

Participant organisation names	Project title	Proposed project costs	Proposed project grant
Arc Trinova Limited	Project Fill-Inova: Enabling flexible and agile highly potent medicines manufacture	£2,072,790	£1,036,395

Note: you can see all Innovate UK-funded projects here: https://www.gov.uk/government/publications/innovate-uk-funded-projects
Use the Competition Code given above to search for this competition's results

Project description - provided by applicants
Arcinova is an agile contract medicines manufacturing organisation. Our vision is to improve Patient Care through transformational technology and integrated solutions as a trusted partner for our customers delivering therapeutic outcomes. Our Fill-Inova Project will use state of the art robotics and digital manufacturing technologies to improve the production of medicines for bespoke, tailored, patient-centric therapies.

Note: you can see all Innovate UK-funded projects here: https://www.gov.uk/government/publications/innovate-uk-funded-projects
Use the Competition Code given above to search for this competition's results

Results of Competition: Digitalisation of Medicines Manufacturing: Challenge Fund

Competition Code: 1810_CRD_ASHN_DIGMM

Total available funding is £8 million

Note: These proposals have succeeded in the assessment stage of this competition. All are subject to grant offer and conditions being met.

Participant organisation names	Project title	Proposed project costs	Proposed project grant
Oxford BioMedica (UK) Limited	Digitalisation of Medicines Manufacturing	£3,990,000	£1,995,000

Note: you can see all Innovate UK-funded projects here: https://www.gov.uk/government/publications/innovate-uk-funded-projects
Use the Competition Code given above to search for this competition's results

Project description - provided by applicants
Oxford BioMedica (OXB) is a company with broad and global market-leading capabilities in terms of development, manufacture and testing of lentiviral vectors for clinical and commercial use. As a platform and product developer OXB pioneered in vivo delivery of lentiviral vectors. Through a partnership with Novartis, OXB is the sole manufacturer of lentiviral vector in support of Kymriah™, the worlds' first commercially approved product based on lentiviral vector technology. OXB is a rapidly growing UK-based organisation specialised in the development and manufacture of ATMPs, and needs to continue to invest in technology, capacity and innovation in order to grow and retain market share. OXB is at the forefront of lentiviral vector development and supply and is seeking to invest long term to maintain this lead. OXB seeks support for a £4million capital project focused on building a digital and robotics framework across OXB, with targetted capacity improvement, reduced waste and reduce cost of manufacture. The project, known as Digital Framework Project (DFP) goal is to drive improvements in analytical methodology, supply times and cost of goods . The DFP will enable OXB and our partners to deliver life altering lentiviral vector products to patients around the globe for a wide range of diseases. This investment will enable OXB to maintain our global leading position, and will ensure additional high value digital driven revenue generating activities can be realised in the UK.